Mesoblast Limited (ASX:MSB)
2.660
-0.090 (-3.27%)
Feb 21, 2025, 4:10 PM AEST
Mesoblast Revenue
In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M USD, down -21.32%. Mesoblast had revenue of $1.26M in the quarter ending June 30, 2024, a decrease of -41.23%.
Revenue
$5.90M
Revenue Growth
-21.32%
P/S Ratio
296.73
Revenue / Employee
$80.85K
Employees
73
Market Cap
3.38B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Telix Pharmaceuticals | 783.21M |
Ramsay Health Care | 16.66B |
Ansell | 3.00B |
Regis Healthcare | 1.01B |
Mesoblast News
- 7 days ago - Mesoblast: Ryoncil Approval Overshadowed By Commercial Hurdles - Seeking Alpha
- 8 days ago - Mesoblast Ltd (MESO) Showcases FDA-Approved Ryoncil® at Prestigious Transplantation Conference - GuruFocus
- 8 days ago - Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings - GlobeNewsWire
- 22 days ago - Mesoblast reports Q2 results - Seeking Alpha
- 22 days ago - Mesoblast Ltd (MESO) Announces U.S. Launch of Ryoncil® and Strategic Pipeline Developments - GuruFocus
- 22 days ago - Ryoncil® Commercial Launch Update and Product Pipeline - GlobeNewsWire
- 22 days ago - Mesoblast Ltd (MESO) Announces Key Developments and Financial Highlights for Q2 2024 - GuruFocus
- 22 days ago - Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - GlobeNewsWire